Ōsaka, Japan
Ōsaka, Japan

Time filter

Source Type

Patent
Kyowa Hakko Kirin Co. | Date: 2016-10-27

The present invention provides a lipid nano-particles, which allow nucleic acids to be easily introduced into cells, comprising a cationic lipid represented by formula (I) (wherein: R^(1 )and R^(2 )are, the same or different, alkenyl, etc, and


Patent
Kyowa Hakko Kirin Co. and Kyushu University | Date: 2016-12-09

Disclosed are an anti-human TIM-3 antibody having high ADCC activity or antibody fragment thereof by screening a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient.


Patent
Pfizer and Kyowa Hakko Kirin Co. | Date: 2015-05-15

The present disclosure describes combination therapies comprising an antibody which specifically binds to human CCR4 and a selective 4-1BB agonist, and the use of the combination therapies for the treatment of cancer.


The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.


Patent
Kyowa Hakko Kirin Co. | Date: 2015-04-16

The problem is to provide a method that can quickly and efficiently evaluate the toxicity of human cerebrospinal fluid (CSF) with small amounts of human CSF. The problem is solved by a method comprising administering human CSF into the cerebral ventricle of a rodent such as a mouse, and evaluating the cognitive function of the rodent by using a behavioral pharmacological technique.


As a technique capable of culturing anchorage-dependent cells without using an anchorage, provided is a medium for anchorage-dependent cells, which comprises MFG-E8 (Milk fat globule-EGF factor 8) or a fragment of the protein. This medium can promote adhesion of anchorage-dependent cells in the absence of an anchorage, enables the survival and proliferation (colony formation) of the cells, and further, also enables the subsequent differentiation if the anchorage-dependent cells are stem cells.


Patent
Kyowa Hakko Kirin Co. | Date: 2017-02-15

An oligonucleotide having a nucleotide residue or a nucleoside residue represented by formula (I) {wherein X^(1) is an oxygen atom or the like, R^(1) is formula (IIA) (wherein R^(5A) is halogen or the like, and R^(6A) is a hydrogen atom or the like) , formula (IVA) (wherein Y^(3A) is a nitrogen atom or the like, and Y^(4A) is CH or the like), or the like, R^(2) is a hydrogen atom, hydroxy, halogen, or optionally substituted lower alkoxy, and R^(3) is a hydrogen atom or the like, or formula (VI)(wherein n2 is 1, 2 or 3)} at the 5 end thereof, wherein the nucleotide residue or the nucleoside residue binds to an adjacent nucleotide residue through the oxygen atom at position 3, is provided.


Patent
Kyowa Hakko Kirin Co. | Date: 2017-02-22

The problem is to provide a method that can quickly and efficiently evaluate the toxicity of human cerebrospinal fluid (CSF) with small amounts of human CSF. The problem is solved by a method comprising administering human CSF into the cerebral ventricle of a rodent such as a mouse, and evaluating the cognitive function of the rodent by using a behavioral pharmacological technique.


Patent
Kyowa Hakko Kirin Co. | Date: 2017-01-18

The present invention provides a nucleic acid having activity to suppress expression of IRF5, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis and the like.


Provided are: a preparation method for an aqueous solution that performs stable filtration in a short time and which has high versatility and improved membrane filtration; an aqueous solution prepared using the preparation method; a cell culturing method using the aqueous solution prepared using the preparation method; a production method for a physiologically active substance using the culturing method; the physiologically active substance produced using the aqueous solution production method; a method for membrane filtration of the aqueous solution prepared using the aqueous solution preparation method; a method for improving the membrane filtration of the aqueous solution; and a method for preparing the aqueous solution, membrane filtrating same, culturing cells using the aqueous solution, and producing the physiologically active substance. The present invention pertains to an aqueous solution preparation method characterized by the addition of a chelating agent.

Loading Kyowa Hakko Kirin Co. collaborators
Loading Kyowa Hakko Kirin Co. collaborators